Table 3.
Management and clinical outcomes of pediatric patients with COVID-19.
| Non-MIS-C | MIS-C | Total | |
|---|---|---|---|
| n = 69 | n = 10 | n = 79 | |
| n (%) or median (IQR) | n (%) or median (IQR) | n (%) or median (IQR) | |
| Management and outcomes | |||
| Oxygen therapy only | 28 (41) | 4 (40) | 32 (41) |
| Non-invasive ventilation only | 4 (6) | 1 (10) | 5 (6) |
| Invasive mechanical ventilation | 13 (19) | 1 (10) | 14 (18) |
| Days of use, median (IQR) | 8.0 (6.0, 11.0) | 5.0 (5.0, 5.0) | 7.5 (5.0, 10.0) |
| Higher PEEP, median (IQR) | 9.0 (7.0, 11.0) | 12.0 (12.0, 12.0) | 9.5 (7.0, 12.0) |
| Intermittent prone position | 3 (100) | 0 (0) | 3 (21) |
| Alveolar recruitment | 4 (44) | 0 (0) | 4 (29) |
| Neuromuscular blocking | 5 (7) | 1 (10) | 6 (43) |
| ARDS diagnosis | 9 (13) | 1 (10) | 10 (13) |
| Mild | 4 (44) | 0 (0) | 4 (40) |
| Moderate | 0 (0) | 0 (0) | 0 (0) |
| Severe | 5 (56) | 1 (100) | 6 (60) |
| Pulmonary arterial hypertension | 2 (3) | 0 (0) | 2 (3) |
| Pharmacologic treatment | |||
| Antibiotics | 52 (75) | 8 (80) | 60 (76) |
| Oseltamivir | 32 (46) | 2 (20) | 34 (43) |
| Antifungal therapy | 3 (4) | 1 (10) | 4 (5) |
| Corticosteroids | 16 (23) | 2 (20) | 18 (23) |
| Hydroxychloroquine | 0 (0) | 0 (0) | 0 (0) |
| PICU LOS, days, median (IQR) | 5.0 (2.8, 10.0) | 5.5 (2.8, 7.5) | 5.0 (2.2, 10.0) |
| Outcomes | |||
| Discharge | 62 (90) | 9 (90) | 71 (90) |
| Death | 2 (3) | 0 (0) | 2 (3) |
| Transfer to other hospital | 5 (7) | 1 (10) | 6 (8) |
ARDS, acute respiratory distress syndrome; IQR, interquartile range; LOS, length of stay; PEEP, positive end expiratory pressure; PICU, pediatric intensive care unit.